Get Adobe Flash player
IntenseMuscle.com
   








Go Back   IntenseMuscle.com > Main Forums > Preventative Measures-health news > THE FDA, CDC, NIH, and RX companies

THE FDA, CDC, NIH, and RX companies What is going on in government, politics, and corporate America in regards to health and medicine.

Reply
 
Thread Tools Display Modes
Old 10-09-2004, 06:29 PM   #1
SuperSport
Heavyweight Member
 
Join Date: Feb 2004
Location: Carolina Beach, NC
Posts: 2,378
Carcinogenicity of lipid-lowering drugs

Carcinogenicity of lipid-lowering drugs.

Newman TB, Hulley SB.

http://www.ncbi.nlm.nih.gov/entrez/q...&dopt=Abstract

Department of Laboratory Medicine, School of Medicine, University of California, San Francisco, USA.

OBJECTIVE--To review the findings and implications of studies of rodent carcinogenicity of lipid-lowering drugs.

DATA SOURCES--Summaries of carcinogenicity studies published in the 1992 and 1994 Physicians' Desk Reference (PDR), additional information obtained from the US Food and Drug Administration, and published articles identified by computer searching, bibliographies, and consultation with experts.

STUDY SAMPLE--We tabulated rodent carcinogenicity data from the 1994 PDR for all drugs listed as "hypolipidemics."

For comparison, we selected a stratified random sample of antihypertensive drugs. We also reviewed methods and interpretation of carcinogenicity studies in rodents and results of clinical trials in humans.

DATA SYNTHESIS--All members of the two most popular classes of lipid-lowering drugs (the fibrates and the statins) cause cancer in rodents, in some cases at levels of animal exposure close to those prescribed to humans.

In contrast, few of the antihypertensive drugs have been found to be carcinogenic in rodents. Evidence of carcinogenicity of lipid-lowering drugs from clinical trials in humans is inconclusive because of inconsistent results and insufficient duration of follow-up.

CONCLUSIONS--Extrapolation of this evidence of carcinogenesis from rodents to humans is an uncertain process. Longer-term clinical trials and careful postmarketing surveillance during the next several decades are needed to determine whether cholesterol-lowering drugs cause cancer in humans.

In the meantime, the results of experiments in animals and humans suggest that lipid-lowering drug treatment, especially with the fibrates and statins, should be avoided except in patients at high short-term risk of coronary heart disease.

Publication Types:
Review
Review Literature

PMID: 8531288 [PubMed]
_________________
__________________
[email protected]
To view links or images in signatures your post count must be 2 or greater. You currently have 0 posts.


" We know that to err is human, but the HIV/AIDS hypothesis is one hell of a mistake"
Dr. Kary Mullis, Nobel Prize Winner in Chemistry for inventing the Polymerase Chain Reaction


"The fact is that you can not start off with bad science and end up with good medicine"


To view links or images in signatures your post count must be 2 or greater. You currently have 0 posts.
SuperSport is offline   Reply With Quote
Old 05-29-2018, 11:49 PM   #2
p70-S6K
New Member
 
Join Date: May 2018
Posts: 5
thanks
p70-S6K is offline   Reply With Quote
Reply

Bookmarks

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off



All times are GMT -4. The time now is 09:49 AM.






Powered by vBulletin
Copyright 2000 - 2009, Jelsoft Enterprises Ltd.

Indexed by Enginuity